Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2025. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Commission file number: 001-35376 OBLONG, INC. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Id ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________________to___________________________ Commission File Number: 001-42374 SYNERGY CHC CORP. (Exact name of registrant as specified in its charter ...

财务数据关键指标变化 - 公司预计截至2025年6月30日现金及投资余额约为3960万美元（未审计）[4] 各条业务线表现 - 3%浓度Repibresib凝胶在关键次要终点F-VASI基线变化百分比上显示-43.6%，而安慰剂组为-25.6%，具有名义统计学显著性[2][6] - 3%浓度Repibresib在探索性终点T-VASI基线变化百分比上显示-28.3%，安慰剂组为-16.2%[2][7] - 试验未达到主要终点F-VASI50（3%组19.5% vs 安慰剂组23.4%）和关键次要终点F-VASI75（3%组9.8% vs 安慰剂组6.4%）[5] - 3%浓度组停药率高达36.6%，显著高于安慰剂组的10.6%[2] - 应用部位疼痛是最常见不良事件（3%组14.0%，安慰剂组3.8%）[8] - 皮肤相关治疗 emergent不良事件中76.0%为轻度，23.7%为中度[8] 管理层讨论和指引 - 公司将终止试验扩展阶段并寻求外部合作伙伴继续开发Repibresib[1][4] - 公司计划在未来几周更新口服BET抑制剂VYN202的开发计划[4] 其他重要内容 - 试验共纳入177名受试者，在北美45个中心进行[3]

Exhibit 99.1 Sow Good Reports Second Quarter 2025 Results IRVING, TEXAS, August 14, 2025 – Sow Good Inc. (Nasdaq: SOWG) ("Sow Good" or "the Company"), a trailblazer in the freeze-dried dried candy and treat industry, is reporting financial and operating results for the six months ended June 30, 2025. "The second quarter marked a meaningful turning point for Sow Good," said Claudia Goldfarb, CEO of Sow Good. "Operations continued to stabilize, and we saw sustained momentum and growing demand for our brand. W ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission file number: 001-39834 CLENE INC. (Exact name of registrant as specified in its charter) | Delaware 85-2828339 | | | ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number 001-41104 VOLATO GROUP, INC. (Exact name of Registrant as specified in its charter) (State or ot ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number 001-41104 VOLATO GROUP, INC. (Exact name of Registrant as specified in its charter) (State or ot ...

FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38418 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 COCRYSTAL PHARMA, INC. (Exact name of registrant as specified in its charter) | Delaware | 35-2528215 | | --- | --- | | (State or Oth ...

Exhibit 99.1 Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of Profitability WESTBROOK, Maine, August 14, 2025 – Synergy CHC Corp. (NASDAQ: SNYR) ("Synergy" or the "Company"), a consumer health and wellness company, is announcing its financial results for the three months ended June 30, 2025. "We are pleased to report another strong quarter, marking our tenth consecutive quarter of profitability," said Jack Ross, CEO of Synergy. "Revenue, gross profit, net i ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025. or (201) 488-0460 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact name of registrant a ...